Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.44 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.44 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.44 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.44 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1805052 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1CYP3A4CA12 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28493 | 0.83 | ALDH1A1 (1.00) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL17203652 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL522122 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CYP3A4CA12 | |
| SCHEMBL3842796 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL17204349 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28834629 | 0.80 | ALDH1A1 (0.79) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28740008 | 0.79 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28416912 | 0.79 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28557531 | 0.79 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 803 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970328-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-04-26 | — | — | EP | claimed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | claimed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | claimed |
| WO-2014140086-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | claimed |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | claimed |
| US-20100130784-A1 | SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROPAN-2-OL COMPOUNDS | PFIZER INC. | 2010-05-27 | — | — | US | claimed |
| EP-1115693-B9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1856060-A1 | SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROP AN-2-OL COMPOUNDS | Pfizer Products Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1115693-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-05-02 | — | — | EP | claimed |
| US-7122536-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2006-10-17 | — | — | US | claimed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000078795-A2 | RUFOMYCINS AND DERIVATIVES THEREOF USEFUL AS INHIBITORS OF MULTI-DRUG RESISTANCE ASSOCIATED PROTEIN-1 (MRP-1) | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0256537-B1 | COLOR PRINT AND A METHOD FOR PRODUCING THE SAME | FUJI PHOTO FILM CO., LTD. (JP) | 1992-12-30 | — | — | EP | claimed |
| US-4857444-A | PHOTOSTABILITY, DISCOLORATION INHIBITION | FUJI PHOTO FILM CO., LTD. (JP) | 1989-08-15 | — | — | US | claimed |
| EP-0320753-A2 | Derivatives of cyclic aminoacids, their preparation, compounds containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-06-21 | — | — | EP | claimed |
| EP-0286927-A2 | Pyrrolidine-2-(1,3-dicarbonyl) derivatives, process for their preparation, agents containing them as well as their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-10-19 | — | — | EP | claimed |
| EP-0256537-A2 | Color print and a method for producing the same | FUJI PHOTO FILM CO., LTD. (JP) | 1988-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | PDE5A, PDE3A, PDE3B | ALDH1A1 743/4885CYP1A1 83/4885CYP1B1 67/4885 |
| US-20100130784-A1 | SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROPAN-2-OL COMPOUNDS | APOB, LDLR, HDLBP | ALDH1A1 1173/4885CYP1A1 648/4885CYP1B1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.